As of April 4, 2026, Steris plc's estimated intrinsic value ranges from $93.67 to $388.71 per share, depending on the valuation methodology applied.
| Valuation Method | Fair Value (USD) | Implied Upside/Downside |
|---|---|---|
| Discounted Cash Flow (10Y) | $388.71 | +77.7% |
| Discounted Cash Flow (5Y) | $293.03 | +34.0% |
| Dividend Discount Model (Multi-Stage) | $237.84 | +8.7% |
| Dividend Discount Model (Stable) | $190.67 | -12.8% |
| Earnings Power Value | $93.67 | -57.2% |
Is Steris plc (STE) undervalued or overvalued?
With the current market price at $218.71, the stock appears to be significantly undervalued.
Intrinsic value represents the "true" worth of a company based on its fundamentals rather than market sentiment. We've employed multiple methodologies to triangulate Steris plc's intrinsic value, including:
The cost of capital is a critical factor in valuation models, representing the required return for investors.
| WACC Component | Low | High |
|---|---|---|
| Long-term bond rate | 3.9% | 4.4% |
| Equity market risk premium | 4.6% | 5.6% |
| Adjusted beta | 0.71 | 0.84 |
| Cost of equity | 7.1% | 9.5% |
| Cost of debt | 4.0% | 4.6% |
| Tax rate | 23.0% | 23.2% |
| Debt/Equity ratio | 0.09 | 0.09 |
| After-tax WACC | 6.8% | 9.0% |
Our DCF model projects cash flows over 5-year and 10-year horizons, with the following key assumptions:
| DCF Model | Fair Value | Enterprise Value | % from Terminal Value |
|---|---|---|---|
| 5-Year Growth | $293 | $30,215M | 85.8% |
| 10-Year Growth | $389 | $39,600M | 73.9% |
| 5-Year EBITDA | $285 | $29,461M | 85.4% |
| 10-Year EBITDA | $374 | $38,199M | 72.9% |
The DDM values a company based on its expected future dividend payments. We used two approaches:
EPV assesses a company's value based on its current normalized earnings power, assuming no growth.
| EPV Component | Value |
|---|---|
| Normalized Earnings | $826M |
| Discount Rate (WACC) | 9.0% - 6.8% |
| Enterprise Value | $9,150M - $12,173M |
| Net Debt | $1,475M |
| Equity Value | $7,676M - $10,698M |
| Outstanding Shares | 98M |
| Fair Value | $78 - $109 |
| Selected Fair Value | $93.67 |
| Metric | Value |
|---|---|
| Market Capitalization | $21451M |
| Enterprise Value | $22926M |
| Trailing P/E | 30.31 |
| Forward P/E | 26.94 |
| Trailing EV/EBITDA | 14.70 |
| Current Dividend Yield | 109.67% |
| Dividend Growth Rate (5Y) | 13.22% |
| Debt-to-Equity Ratio | 0.09 |
To determine the most reliable intrinsic value estimate, we weigh each valuation method based on:
| Valuation Method | Weight | Weighted Value |
|---|---|---|
| Discounted Cash Flow (10Y) | 30% | $116.61 |
| Discounted Cash Flow (5Y) | 25% | $73.26 |
| Dividend Discount Model (Multi-Stage) | 20% | $47.57 |
| Dividend Discount Model (Stable) | 15% | $28.60 |
| Earnings Power Value | 10% | $9.37 |
| Weighted Average | 100% | $275.41 |
Based on our comprehensive valuation analysis, Steris plc's intrinsic value is $275.41, which is approximately 25.9% above the current market price of $218.71.
Key investment considerations:
Given these factors, we believe Steris plc is currently significantly undervalued with the potential for long-term appreciation based on the company's growth trajectory and financial strength.